Uwe Platzbecker

Active 2000–2025

330
Papers
32,331
Citations
87
h-index
299
i10-index

Citations

Citations per year for Uwe Platzbecker1989: 1 citations2001: 1 citations2002: 4 citations2003: 33 citations2004: 39 citations2005: 43 citations2006: 33 citations2007: 37 citations2008: 39 citations2009: 43 citations2010: 56 citations2011: 50 citations2012: 69 citations2013: 115 citations2014: 132 citations2015: 136 citations2016: 153 citations2017: 165 citations2018: 163 citations2019: 742 citations2020: 932 citations2021: 1,119 citations2022: 1,067 citations2023: 1,189 citations2024: 2,011 citations2025: 1,086 citations2026: 19 citations1990–2000: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,748 citing papers, 23.7% of this breakdownGermany: 1,154 citing papers, 10% of this breakdownItaly: 851 citing papers, 7.3% of this breakdownChina: 829 citing papers, 7.2% of this breakdownUnited Kingdom: 738 citing papers, 6.4% of this breakdownFrance: 648 citing papers, 5.6% of this breakdownSpain: 451 citing papers, 3.9% of this breakdownNetherlands: 359 citing papers, 3.1% of this breakdownCanada: 326 citing papers, 2.8% of this breakdownAustralia: 281 citing papers, 2.4% of this breakdownJapan: 260 citing papers, 2.2% of this breakdownSwitzerland: 232 citing papers, 2% of this breakdown
0%23.7%Other 23.4%

Fields

  • Medicine73.9%
  • Biochemistry, Genetics and Molecular Biology18.3%
  • Immunology and Microbiology4.8%
  • Computer Science1.4%
  • Engineering0.3%
  • Neuroscience0.3%
  • Other1%

Topics

  • Acute Myeloid Leukemia Research17.7%
  • Myeloproliferative Neoplasms: Diagnosis and Treatment6.6%
  • Hematopoietic Stem Cell Transplantation5.1%
  • Chronic Myeloid Leukemia Treatments4%
  • Acute Lymphoblastic Leukemia research3.3%
  • Retinoids in leukemia and cellular processes2.7%
  • Other60.6%

Coauthors

All papers

Open in search
  1. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Joop H. Jansen, Rashmi Kanagal‐Shamanna, Hagop M. Kantarjian, Christian P. Kratz, Xiaoqiu Li, Megan S. Lim, Keith R. Loeb, Sanam Loghavi, Andrea N. Marcogliese, Soheil Meshinchi, Phillip Michaels, Kikkeri N. Naresh, Yasodha Natkunam, Reza Nejati, German Ott, Eric Padron, Keyur P. Patel, Nikhil Patkar, Jennifer Picarsic, Uwe Platzbecker, Irene Roberts, Anna Schuh, William A. Sewell, Reiner Siebert, Prashant Tembhare, Jeffrey Tyner, Srđan Verstovšek, Wei Wang, Brent L. Wood, Wenbin Xiao, Cecilia C.S. Yeung, Andreas Hochhaus - Leukemia 2022 cited by 3,904

  2. Molecular International Prognostic Scoring System for Myelodysplastic Syndromes

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Akifumi Takaori‐Kondo, Takayuki Ishikawa, Shigeru Chiba, Senji Kasahara, Yasushi Miyazaki, Agnès Viale, Kety Huberman, Pierre Fenaux, Monika Beličková, Michael R. Savona, Virginia M. Klimek, Fábio Pires de Souza Santos, Jacqueline Boultwood, Ιoannis Kotsianidis, Valeria Santini, Françesc Solé, Uwe Platzbecker, Michael Heuser, Peter Valent, Kazuma Ohyashiki, Carlo Finelli, Maria Teresa Voso, Lee‐Yung Shih, Michaëla Fontenay, Joop H. Jansen, José Cervera, Norbert Gattermann, Benjamin L. Ebert, Rafael Bejar, Luca Malcovati, Mario Cazzola, Seishi Ogawa, Eva Hellström‐Lindberg, Elli Papaemmanuil - NEJM Evidence 2022 cited by 813

  3. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jacqueline Boultwood, Fábio Pires de Souza Santos, Julie Schanz, Senji Kasahara, Takayuki Ishikawa, Hisashi Tsurumi, Akifumi Takaori‐Kondo, Toru Kiguchi, Chantana Polprasert, John M. Bennett, Virginia M. Klimek, Michael R. Savona, Monika Beličková, Christina Ganster, Laura Palomo, Guillermo Sanz, Lionel Adès, Matteo Giovanni Della Porta, Harold K. Elias, Alexandra Smith, Yesenia Werner, Minal Patel, Agnès Viale, Katelynd Vanness, Donna Neuberg, Kristen E. Stevenson, Kamal Menghrajani, Kelly L. Bolton, Pierre Fenaux, Andrea Pellagatti, Uwe Platzbecker, Michael Heuser, Peter Valent, Shigeru Chiba, Yasushi Miyazaki, Carlo Finelli, Maria Teresa Voso, Lee‐Yung Shih, Michaëla Fontenay, Joop H. Jansen, José Cervera, Yoshiko Atsuta, Norbert Gattermann, Benjamin L. Ebert, Rafael Bejar, Peter L. Greenberg, Mario Cazzola, Eva Hellström-Lindberg, Seishi Ogawa, Elli Papaemmanuil - Nature Medicine 2020 cited by 636

  4. Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Hartmut Link, Maria Grazia Kropp, Alessandro Rambaldi, Giorgio La Nasa, Mario Luppi, Fabio Ciceri, Olimpia Finizio, Adriano Venditti, Francesco Fabbiano, Konstanze Döhner, Michaela Sauer, Arnold Ganser, Sergio Amadori, Franco Mandelli, Hartmut Döhner, Gerhard Ehninger, Richard F. Schlenk, Uwe Platzbecker - New England Journal of Medicine 2013 cited by 1,606

  5. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Amer M. Zeidan, Lionel Adès, Amit Verma, Michael R. Savona, Abderrahmane Laadem, Aziz Benzohra, Jennie Zhang, Anita Rampersad, Diana Dunshee, Peter G. Linde, Matthew L. Sherman, Rami S. Komrokji, Alan F. List - New England Journal of Medicine 2020 cited by 537

  6. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet

    Authors: , , , , , , , , , , , , , , , , , , , , - Blood 2019 cited by 655

  7. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2023 cited by 164

  8. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ernst Forjan, Emanuil Gheorghita, Richard Greil, Antónia Hatalova, M Hrubisko, János Jakucs, Polina Kaplan, Sergiy Klymenko, Steffen Koschmieder, Mihaela Lazaroiu, Tamila Lysa, Zvenyslava Masliak, Tamás Masszi, Georgi Mihaylov, Alexander Myasnikov, Uwe Platzbecker, Mathieu Puyade, Jérôme Rey, Lydia Roy, Jiřı́ Schwarz, Aleksander B. Skotnicki, I. Ya. Sokolova, Maria Soroka‐Wojtaszko, Jolanta Starzak-Gwóźdź, Vera Stoeva, Jose Miguel Torregrosa‐Diaz, Anna Vallova, Elena Volodicheva, Krzysztof Warzocha, Ella Willenbacher, Dominik Wolf‎ - The Lancet Haematology 2020 cited by 347

  9. Synthetic Data Generation by Artificial Intelligence to Accelerate Research and Precision Medicine in Hematology

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - JCO Clinical Cancer Informatics 2023 cited by 87

  10. Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2023 cited by 132

  11. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial

    Authors: , , , , , , , , , , , , - The Lancet Haematology 2017 cited by 315

  12. Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Benoit Destenaves, Xiaobin Yuan, Kun Yu, Sara Dar, Lernik Ohanjanian, Keisuke Kuida, Jianjun Xiao, Catherine Scholz, Antonio Gualberto, Uwe Platzbecker - Leukemia 2021 cited by 178

  13. Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Polina Stepensky, Al‐Ola Abdallah, Carlos Fernández de Larrea - Journal of Clinical Oncology 2024 cited by 83

  14. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christian Thiede - The Lancet Oncology 2018 cited by 354

  15. Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML

    Authors: , , , , , , , , , , , , , , , , , , - Blood Advances 2022 cited by 121

  16. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2017 cited by 376

  17. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Katja Sockel, Malte von Bonin, Carsten Müller‐Tidow, Uwe Platzbecker, Wolfgang E. Berdel, Hubert Serve, Gerhard Ehninger, Martin Bornhäuser, Johannes Schetelig, Christian Thiede, for the Study Alliance Leukemia (SAL) - Blood 2021 cited by 164

  18. Deep learning identifies Acute Promyelocytic Leukemia in bone marrow smears

    Authors: , , , , , , , , , , , , , , , , - BMC Cancer 2022 cited by 76

  19. Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Fabio Ciceri, Jaime Sanz, Ali Bazarbachi, Arnon Nagler, Mohamad Mohty - Bone Marrow Transplantation 2020 cited by 203

  20. Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Binje Vick, Irmela Jeremias, Andreas Trumpp, Jeroen Krijgsveld, Carsten Müller‐Tidow, Sascha Dietrich - Blood 2022 cited by 102

  21. Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Phillip Scheinberg, Reinhard Stauder, Arjan A. van de Loosdrecht, Andrew H. Wei, Mikkael A. Sekeres, Pierre Fenaux - Blood 2023 cited by 92

  22. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

    Authors: , , , , , , , , , , , - Blood 2002 cited by 1,729

  23. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet

    Authors: , , , , , , , , , , , , , , , , , , , , , - Blood 2013 cited by 667

  24. Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Francesco Passamonti, Fabio Ciceri, Niccolò Bolli, Alessandro Rambaldi, Wolfgang Kern, Shahram Kordasti, Françesc Solé, Laura Palomo, Guillermo Sanz, Armando Santoro, Uwe Platzbecker, Pierre Fenaux, Luciano Milanesi, Torsten Haferlach, Gastone Castellani, Matteo Giovanni Della Porta - Journal of Clinical Oncology 2021 cited by 225